Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | MMP1 | P03956 | 4/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | MMP9 | P14780 | 4/20 | 0.59 |
| ▸ | MMP8 | P22894 | 4/20 | 0.59 |
| ▸ | MMP13 | P45452 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190292 | 0.85 | CA1 (0.70) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL6920158 | 0.83 | KMT2A (0.69) | KMT2AMEN1FBP1ALDH1A1MAPT | |
| SCHEMBL29547938 | 0.82 | KMT2A (0.67) | KMT2AMEN1FBP1ALDH1A1MAPT | |
| SCHEMBL1087618 | 0.82 | KMT2A (0.67) | KMT2AMEN1FBP1ALDH1A1MAPT | |
| SCHEMBL9090583 | 0.81 | FBP1 (0.65) | KMT2AFBP1ALDH1A1MAPTHPGD | |
| SCHEMBL418539 | 0.80 | KMT2A (0.65) | KMT2AMEN1FBP1ALDH1A1MAPT | |
| SCHEMBL22446712 | 0.80 | KMT2A (0.65) | KMT2AMEN1FBP1ALDH1A1MAPT | |
| SCHEMBL29528116 | 0.80 | CA1 (0.57) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL15879184 | 0.80 | CA1 (0.57) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL12520277 | 0.80 | KMT2A (0.65) | KMT2AMEN1FBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066002-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11786501-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190144380-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| EP-3427728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-9968584-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170151210-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9586896-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160031807-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9156804-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150175566-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8987326-B2 | Nitroxyl donors with improved therapeutic index | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140206769-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206769-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | KMT2A 4186/4885CA1 2934/4885CA2 2484/4885 |
| US-11786501-B2 | Nitroxyl donors with improved therapeutic index | TNNI3, TNNT2, TNNC1 | KMT2A 4186/4885CA1 2934/4885CA2 2484/4885 |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | KMT2A 4748/4885CA1 2645/4885CA2 1468/4885 |
| US-20150175566-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | KMT2A 4186/4885CA1 2934/4885CA2 2484/4885 |
| US-20190144380-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, TNNT2 | KMT2A 4748/4885CA1 2645/4885CA2 1468/4885 |
| US-20160031807-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | KMT2A 4186/4885CA1 2934/4885CA2 2484/4885 |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | KMT2A 3220/4885CA1 4828/4885CA2 4041/4885 |
| US-20240066002-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | KMT2A 4186/4885CA1 2934/4885CA2 2484/4885 |
| US-20170151210-A1 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | TNNI3, TNNT2, TNNC1 | KMT2A 4186/4885CA1 2934/4885CA2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.